MYC overexpression drives poor prognosis and differential sensitivity to treatments according to TP53 status in chronic lymphocytic leukemia
Alba Garrote-de-Barros, Juan Pérez‐Fernández, Andrés Arroyo-Barea, Irene Bragado-García, Roberto García-Vicente, Raquel Ancos-Pintado, María Velasco‐Estevez, María Linares, Joaquín Martínez‐López, María Hernández‐Sánchez
This study shows that MYC overexpression in CLL worsens prognosis and treatment response, with different effects based on TP53 status.
bioRxiv · May 18, 2026 · PreprintCancer Biology